Antibiotic Resistance Evolution Group, Max-Planck-Institute for Evolutionary Biology, 24306 Plön, Germany.
Department of Evolutionary Ecology and Genetics, Zoological Institute, Christian-Albrechts-Universität zu Kiel, 24118 Kiel, Germany.
Proc Natl Acad Sci U S A. 2018 Sep 25;115(39):9767-9772. doi: 10.1073/pnas.1810004115. Epub 2018 Sep 12.
Antibiotic resistance has become one of the most dramatic threats to global health. While novel treatment options are urgently required, most attempts focus on finding new antibiotic substances. However, their development is costly, and their efficacy is often compromised within short time periods due to the enormous potential of microorganisms for rapid adaptation. Here, we developed a strategy that uses the currently available antibiotics. Our strategy exploits cellular hysteresis, which is the long-lasting, transgenerational change in cellular physiology that is induced by one antibiotic and sensitizes bacteria to another subsequently administered antibiotic. Using evolution experiments, mathematical modeling, genomics, and functional genetic analysis, we demonstrate that sequential treatment protocols with high levels of cellular hysteresis constrain the evolving bacteria by () increasing extinction frequencies, () reducing adaptation rates, and () limiting emergence of multidrug resistance. Cellular hysteresis is most effective in fast sequential protocols, in which antibiotics are changed within 12 h or 24 h, in contrast to the less frequent changes in cycling protocols commonly implemented in hospitals. We found that cellular hysteresis imposes specific selective pressure on the bacteria that disfavors resistance mutations. Instead, if bacterial populations survive, hysteresis is countered in two distinct ways, either through a process related to antibiotic tolerance or a mechanism controlled by the previously uncharacterized two-component regulator CpxS. We conclude that cellular hysteresis can be harnessed to optimize antibiotic therapy, to achieve both enhanced bacterial elimination and reduced resistance evolution.
抗生素耐药性已成为全球健康面临的最严峻威胁之一。虽然急需新型治疗方案,但大多数尝试都集中于寻找新的抗生素物质。然而,由于微生物具有快速适应的巨大潜力,它们的开发成本高昂,而且往往在短时间内疗效就会受到影响。在这里,我们开发了一种利用现有抗生素的策略。我们的策略利用了细胞滞后现象,即一种抗生素诱导的细胞生理学的持久、跨代变化,使细菌对随后给予的另一种抗生素敏感。通过进化实验、数学建模、基因组学和功能遗传分析,我们证明,具有高细胞滞后的序贯治疗方案通过以下方式限制了进化中的细菌:()增加灭绝频率,()降低适应率,()限制多药耐药性的出现。与医院中常用的循环方案中较少的抗生素变化相比,在快速序贯方案中,细胞滞后最为有效,抗生素在 12 小时或 24 小时内发生变化。我们发现,细胞滞后对细菌施加了特定的选择压力,不利于耐药突变的出现。相反,如果细菌种群存活下来,滞后会通过两种不同的方式得到抵消,一种与抗生素耐受有关的过程,或者一种由以前未被描述的双组分调节因子 CpxS 控制的机制。我们的结论是,细胞滞后可以被利用来优化抗生素治疗,以实现增强细菌消除和减少耐药进化的双重效果。